MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q2
hinzugefügt 16.05.2026
Timber Pharmaceuticals Betriebsaufwand 2011-2026 | TMBR
Betriebsaufwand Jährlich Timber Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.3 M | 11.5 M | 20.7 M | 3.31 M | 16.7 M | 18 M | 15 M | 1.14 M | 7.77 M | 1.51 M | 83 K | - | 5.54 K |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 20.7 M | 5.54 K | 9.59 M |
Betriebsaufwand Vierteljährlich Timber Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 M | 4 M | - | 3.13 M | 9.4 M | 3.22 M | - | 3.27 M | 3.36 M | 1.91 M | - | 1.92 M | 14.3 M | 1.62 M | - | 2.12 M | 2.66 M | 3.64 M | - | 3.74 M | 4.28 M | 5.04 M | - | 4.17 M | 5.04 M | 4.47 M | - | 3.85 M | 3.57 M | 3.18 M | - | 3.85 M | 3.57 M | 3.18 M | - | 2.08 M | 1.83 M | 1.08 M | - | 429 K | 247 K | 103 K | 2.78 K | 8.16 K | 1.55 K | 95.4 K | 1.3 K | 5.94 K | 1.05 K | 1.3 K |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 14.3 M | 1.05 K | 2.81 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Compugen Ltd.
CGEN
|
32.2 M | $ 2.19 | -1.35 % | $ 205 M |  Israel |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.55 | -1.9 % | $ 182 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
512 M | $ 89.35 | -0.27 % | $ 21.6 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
170 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
54 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 30.0 | 0.22 % | $ 1.99 B | USA |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
98.4 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
214 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 14.63 | -1.08 % | $ 210 M | USA |
 |
Advaxis
ADXS
|
19.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.21 | 1.58 % | $ 5.28 M | Israel |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 54.68 | -3.99 % | $ 4.92 B |  Schweiz |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
305 M | $ 21.95 | - | $ 2.79 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |